Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting

International Journal of Neuropsychopharmacology

Volumn 9, Issue 5, 2006, Pages 529-537

  Letmaier, Martin ^a   Schreinzer, Daniel ^a   Reinfried, Lutz ^a   Glauninger, Georg ^a   Thierry, Nikolaus ^a   Kapitany, Thomas ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atypical antipsychotics; Bipolar disorder; Mania; Retrospective chart review; Treatment pattern; Typical neuroleptics

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; DIAZEPAM; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TOPIRAMATE; TRANQUILIZER; VALPROIC ACID; ZOTEPINE; ZUCLOPENTHIXOL;

ADD ON THERAPY; ADULT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG CHOICE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL RECORD REVIEW; MENTAL PATIENT; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33750215431     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006073     Document Type: Review

References (29)

1. APA (1994). Practice guidelines for the treatment of patients with bipolar disorder. American Journal of Psychiatry 151 (Suppl. 12), 1-36.
2. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K (2005). A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Journal of Clinical Psychiatry 66, 111-121.
3. Cassidy F, Ahearn EP, Carroll BJ (2001). Substance abuse in bipolar disorder. Bipolar Disorders 3, 181-188.
4. Chou JC-Y (1992). Drug treatment of acute mania. Drugs Today 28, 119-130.
5. Goldberg JF (2000). Treatment guidelines: current and future management of bipolar disorder. Journal of Clinical Psychiatry 61 (Suppl. 13), 12-18.
6. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ (2003). The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders Part II: Treatment of Mania. World Journal of Biological Psychiatry 4, 5-13.
7. Hirschfeld RM, Keck Jr. PE, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossmann F (2004). Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. American Journal of Psychiatry 161, 1057-1065.
8. Kasper S, Haushofer M, Zapotoczky HG, Aschauer H, Wolf R, Hinterhuber H, Bonelli M, Wuschitz A (1999). Consensus statement: diagnosis and therapy of bipolar disorders. Neuropsychiatrie 13 (Suppl. 3), 100-108.
9. Kasper S, Stamenkovic M, Letmaier M, Schreinzer D (2002). Atypical antipsychotics in mood disorders. International Clinical Psychopharmacology 17 (Suppl. 3), 1-10.
10. Keck Jr. PE, McElroy SL, Strakowski SM, Soutullo CA (2000). Antipsychotics in the treatment of mood disorders and the risk of tardive dyskinesia. Journal of Clinical Psychiatry 61 (Suppl. 4), 33-38.
11. Keck Jr. PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G (2003b). A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 160, 1651-1658.
12. Keck Jr. PE, Versiani M, Potkin S, West SA, Giller E, Ice K (2003a). Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. American Journal of Psychiatry 160, 741-748.
13. Letmaier M, Schreinzer D, Thierry N, Wolf R, Kasper S (2004). Drug therapy of acute manias. A retrospective data analysis of inpatients from 1997 to 1999. Nervenarzt 75, 249-257.
14. Licht RW (1998). Drug treatment of mania: a critical review. Acta Psychiatrica Scandinavica 97, 387-397.
15. Miller DS, Yatham LN, Lam RW (2001). Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. Journal of Clinical Psychiatry 62, 975-980.
16. Mukherjee S, Rosen AM, Caracci G, Shukla S (1986). Persistent tardive dyskinesia in bipolar patients. Archives of General Psychiatry 43 (Suppl. 4), 342-346.
17. Müller-Oerlinghausen B (1990). Assessment of drug utilisation and adverse drug reactions. In: Bunney WE, Hippius H, Laakman G, Schmauß M (Eds.), Neuropsychopharmacology (pp. 583-597). Berlin, Heidelberg, New York: Springer.
18. Nasrallah HA, Churchill CM, Hamdan-Allan GA (1988). Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. American Journal of Psychiatry 145 (Suppl. 11), 1455-1456.
19. NIMH (1970). 12 - CGI. Clinical Global Impressions. In: Guy W (Ed.), Manual for the EDCEU Assessment in Psychopharmacology, rev. edn (pp. 217-222). Rockville, MD: National Institute of Mental Health.
20. Platman SR (1970). A comparison of lithium carbonate and chlorpromazine in mania. American Journal of Psychiatry 127, 351-353.
21. Sachs G, Grossman F, Ghaemi S, Okamoto A, Bowden C (2002). Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. American Journal of Psychiatry 159 (7), 1146-54.
22. Sachs GS, Printz DJ, Carpenter D (2000). The Expert Consensus Guideline Series: Medication treatment of bipolar disorder. Postgraduate Medicine (Special Issue), 1-104.
23. Segal J, Walton S, Clark H, Berk M (2000). Pharmacotherapy of mania: a review. International Journal of Psychiatry in Clinical Practice 4, 171-193.
24. Svendsen SW (1997). Secular trends in first-ever admission rates of affective disorders in Denmark, 1971-93. Nordic Journal of Psychiatry 51, 119-125.
25. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, et al. (2000). Efficacy of olanzapine in acute mania: a double-blind placebo-controlled study. Archives of General Psychiatry 57, 841-849.
26. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, et al. (1999). Olanzapine versus placebo in the treatment of acute mania. American Journal of Psychiatry 156, 702-709.
27. Tohen M, Zhang F, Taylor CC, Burns P, Zarate C, Sanger T, Tollefs G (2001). A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. Journal of Affective Disorders 65, 85-93.
28. Woggon B (1987). Psychopharmakotherapie affektiver Psychosen. In: Kisker KP, Lauter H, Meyer JE, Müller C, Strömgen E (Eds.), Psychiatrie der Gegenwart, volume 5: Affektive Psychosen, 3rd edn (pp. 273-325). Berlin, Heidelberg, New York: Springer.
29. WHO (1992). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines (10th revision). Geneva: World Health Organization.